◆ Market Data --:--
⛽ Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Microbix Biosystems Inc.

MBX.TO TSX Healthcare Mississauga, Canada
Loading stock data...
Stock Performance
Price History
- Drag to select time range -
Market Data
Market Cap 31.9M
P/E Ratio -
52-Week High -
52-Week Low -
Avg Volume -
Beta -
Forward P/E -
Dividend Yield -
EV/Revenue -
Price/Book -
Business Overview

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Healthcare Biotechnology TSX
Key Financial Metrics
18.6M
Revenue
-2.2M
Net Income
C$-0.02
EPS (Diluted)
-877,584
Free Cash Flow
Profitability
Gross Margin 53.0%
Operating Margin -8.5%
Net Profit Margin -12.1%
EBITDA 428,230
Returns & Efficiency
Return on Assets (ROA) -6.0%
Return on Equity (ROE) -8.1%
Dividend Yield -
Payout Ratio -
Financial Health
Total Assets 37.4M
Total Debt 6.8M
Debt to Equity 0.24x
Current Ratio 8.48
Company Info
IndustryBiotechnology
HQMississauga, Canada
Fiscal Year End1759190400
CurrencyCAD
Websitewww.microbix.com
Peers
7.9B
P/E: --
2.5B
P/E: 12.0
2.5B
P/E: 23.7
2.2B
P/E: 53.2
1.4B
P/E: 24.1
1.2B
P/E: --
1.1B
P/E: --
631.8M
P/E: --
Insider Activity
Sentiment Bullish
Shares Bought 6,005,158
Shares Sold 0
Total Transactions 30
SEDAR+ Filings
View All Filings
19
Annual Reports
15
Quarterly Reports
24
MD&A
139
News Releases
15
Material Changes
2
Governance
48
Certifications
24
Other

● Interim financial statements/report – English.pdf
2026-02-12
● Interim financial statements/report – English.pdf
2025-08-14
● Interim financial statements/report – English.pdf
2024-08-14
● Interim financial statements/report – English.pdf
2024-05-15
● Interim financial statements/report – English.pdf
2023-08-10
View all 15 quarterly reports →

● Interim MD&A - English.pdf
2026-02-12
● Annual MD&A - English.pdf
2025-12-18
● Interim MD&A - English.pdf
2025-08-14
● Annual MD&A - English.pdf
2024-12-19
● Interim MD&A - English.pdf
2024-08-14
View all 24 md&a →

● News release - English.pdf
2026-02-24
● News release - English.pdf
2026-02-12
● News release - English.pdf
2026-02-10
● News release - English.pdf
2026-02-05
● News release - English.pdf
2026-02-04
View all 139 news releases →

● Material change report - English.pdf
2023-11-16
● Material change report - English.pdf
2023-05-18
● Material change report (amended) - English.pdf
2021-12-24
● Material change report - English.pdf
2021-05-19
● Material change report - English.pdf
2020-12-07
View all 15 material changes →

● Form of proxy - English.pdf
2026-02-20
● Management information circular - English.pdf
2026-02-20

● 52-109F2 - Certification of interim filings - CEO (E).pdf
2026-02-12
● 52-109F2 - Certification of interim filings - CFO (E).pdf
2026-02-12
● 52-109F1 - Certification of annual filings - CEO (E).pdf
2025-12-18
● 52-109F1 - Certification of annual filings - CFO (E).pdf
2025-12-18
● 52-109F2 - Certification of interim filings - CEO (E).pdf
2025-08-14
View all 48 certifications →

● Notice of meeting - English.pdf
2026-02-20
● Notice of the meeting and record date (amended) - English.pdf
2026-02-05
● Notice of the meeting and record date - English.pdf
2026-01-12
● AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
2025-12-18
● ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
2025-12-18
View all 24 other →
Interactive Charts
Full Chart View
Company Profile
General Information
Company NameMicrobix Biosystems Inc.
TickerMBX.TO
ExchangeTSX
SectorHealthcare
IndustryBiotechnology
HeadquartersMississauga, Canada
Fiscal Year End1759190400
CurrencyCAD
Websitewww.microbix.com
Financial Summary
Market Cap31.9M
Revenue18.6M
Net Income-2.2M
P/E RatioN/A
EPS (Diluted)C$-0.02
Net Margin-12.1%
ROE-8.1%
Dividend YieldN/A
Business Description
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
NEWS
Loading news...
TRENDING
Loading...